Duncan McLauchlan

Duncan McLauchlan

Auto-generated profile, based on publicly available information

Duncan McLauchlan

Cardiff University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Biological Psychiatry
Verified
Journal Article
Open access
NENatalie Ellis
Natalie Ellis
ATAmelia Tee
Amelia Tee
BMBranduff McAllister
Branduff McAllister
TMThomas Massey
Thomas Massey
DMDuncan McLauchlan
Duncan McLauchlan
PHPeter Holmans
Peter Holmans
Huntington's disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene. It is diagnosed following a standardized examination of motor control and often presents with cognitive decline and psychiatric symptoms. Recent studies have detected genetic loci modifying the age at onset of motor symptoms in HD, but genetic factors influencing cognitive and psychiatric presentations are unknown. We tested the hypothesis that psychiatric and cognitive symptoms in HD are influenced by the same common genetic variation as in the general population by 1) constructing polygenic risk scores from large genome-wide association studies of psychiatric and neurodegenerative disorders and of intelligence and 2) testing for correlation with the presence of psychiatric and cognitive symptoms in a large sample (n = 5160) of patients with HD. Polygenic risk score for major depression was associated specifically with increased risk of depression in HD, as was schizophrenia risk score with psychosis and irritability. Cognitive impairment and apathy were associated with reduced polygenic risk score for intelligence. Polygenic risk scores for psychiatric disorders, particularly depression and schizophrenia, are associated with increased risk of the corresponding psychiatric symptoms in HD, suggesting a common genetic liability. However, the genetic liability to cognitive impairment and apathy appears to be distinct from other psychiatric symptoms in HD. No associations were observed between HD symptoms and risk scores for other neurodegenerative disorders. These data provide a rationale for treatments effective in depression and schizophrenia to be used to treat depression and psychotic symptoms in HD.

30 July 2019 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
DMDuncan J. McLauchlan
Duncan J. McLauchlan
TLThomas Lancaster
Thomas Lancaster
DCDavid Craufurd
David Craufurd
DLDavid E.J. Linden
David E.J. Linden
ARAnne E. Rosser
Anne E. Rosser

9 November 2022 in Brain Communications
Verified
Journal Article
Open access
PDF file
DMDuncan James McLauchlan
Duncan James McLauchlan
TLThomas Lancaster
Thomas Lancaster
DCDavid Craufurd
David Craufurd
DLDavid E J Linden
David E J Linden
ARAnne E Rosser
Anne E Rosser
Depression is more common in neurodegenerative diseases such as Huntington’s disease than the general population. Antidepressant efficacy is well-established for depression within the general population: a recent meta-analysis showed serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants and mirtazapine outperformed other antidepressants. Despite the severe morbidity, antidepressant choice in Huntington’s disease is based on Class IV evidence. We used complementary approaches to determine treatment choice for depression in Huntington’s disease: propensity score analyses of antidepressant treatment outcome using the ENROLL-HD data set, and a dissection of the cognitive mechanisms underlying depression in Huntington’s disease using a cognitive battery based on the Research Domain Criteria for Depression. Study 1 included ENROLL-HD 5486 gene-positive adult patients started on an antidepressant medication for depression. Our outcome measures were depression (Hospital Anxiety and Depression Scale or Problem Behaviours Assessment ‘Depressed Mood’ item) at first follow-up (primary outcome) and all follow-ups (secondary outcome). The intervention was antidepressant class. We used Svyglm&Twang in R to perform propensity scoring, using known variables (disease progression, medical comorbidity, psychiatric morbidity, sedatives, number of antidepressants, demographics and antidepressant contraindications) to determine the probability of receiving different antidepressants (propensity score) and then included the propensity score in a model of treatment efficacy. Study 2 recruited 51 gene-positive adult patients and 26 controls from the South Wales Huntington’s Disease Management Service. Participants completed a motor assessment, in addition to measures of depression and apathy, followed by tasks measuring consummatory anhedonia, motivational anhedonia, learning from reward and punishment and reaction to negative outcome. We used generalised linear models to determine the association between task performance and depression scores. Study 1 showed selective serotonin reuptake inhibitors outperformed serotonin norepinephrine reuptake inhibitors on the primary outcome (P = 0.048), whilst both selective serotonin reuptake inhibitors (P = 0.00069) and bupropion (P = 0.0045) were superior to serotonin norepinephrine reuptake inhibitors on the secondary outcome. Study 2 demonstrated an association between depression score and effort for reward that was not explained by apathy. No other mechanisms were associated with depression score. We found that selective serotonin reuptake inhibitors and bupropion outperform serotonin norepinephrine reuptake inhibitors at alleviating depression in Huntington’s disease. Moreover, motivational anhedonia appears the most significant mechanism underlying depression in Huntington’s disease. Bupropion is improves motivational anhedonia and has a synergistic effect with selective serotonin reuptake inhibitors. This work provides the first large-scale, objective evidence to determine treatment choice for depression in Huntington’s disease, and provides a model for determining antidepressant efficacy in other neurodegenerative diseases.

29 December 2022 in Frontiers in Neuroscience
Verified
Journal Article
Open access
DMDuncan James McLauchlan
Duncan James McLauchlan
DLDavid E. J. Linden
David E. J. Linden
ARAnne E. Rosser
Anne E. Rosser
Background: Irritable and impulsive behaviour are common in Huntington’s disease (HD: an autosomal dominant disorder causing degeneration in cortico-striatal networks). However, the cognitive mechanisms underlying these symptoms remain unclear, and previous research has not determined if common mechanisms underpin both symptoms. Here we used established and novel tasks to probe different aspects of irritable and impulsive behaviour to determine the neural mechanisms involved.Methods: We recruited a cohort of 53 gene positive HD participants and 26 controls from non-affected family members and local volunteers. We used established questionnaire measures of irritability in HD (Snaith Irritability Scale, Problem Behaviours Assessment) and impulsivity [Urgency, Premeditation Perseverance, Sensation-seeking, Positive urgency scale (UPPSP), Barratt Impulsivity Scale], in addition to cognitive tasks of provocation, motor inhibition, delay discounting and decision making under uncertainty. We used generalised linear models to determine differences between cases and controls, and associations with irritability in the HD group.Results: We found differences between cases and controls on the negative urgency subscale of the UPPSP, which was associated with irritability in HD. The frustrative non-reward provocation task also showed differences between cases and controls, in addition to predicting irritability in HD. The stop signal reaction time task showed case-control differences but was not associated with irritability in HD. None of the other measures showed group differences or predicted irritability in HD after correcting for confounding variables.Discussion: Irritability in HD is mediated by excessive response to provocation, rather than a failure of motor inhibition.

26 October 2022 in Clinical Parkinsonism & Related Disorders
Verified
Journal Article
Open access
EHEmily Hare
Emily Hare
ABAnne-Catherine Bachoud-Lévi
Anne-Catherine Bachoud-Lévi
RRRalf Reilmann
Ralf Reilmann
DCDavid Craufurd
David Craufurd
MBMonica Busse
Monica Busse
DMDuncan McLauchlan
Duncan McLauchlan
Disease-modifying treatments for Huntington’s disease (HD) are entering clinical trials: there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD. Evaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD. 83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12 month follow up. The Maze task was found to be the most sensitive measure of change at 12 months, including the current gold-standard measure (the composite disease progression score). The Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.

5 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DMDuncan Mclauchlan
Duncan Mclauchlan
CDCheney Drew
Cheney Drew
PHPeter Holmans
Peter Holmans
ARAnne Rosser
Anne Rosser
Objectives: Determine differences in frequency and choice of antidepressant for anxiety and depression between pwHD and controls. Determine if regional variation affects antidepressant prescribing between pwHD and controls. Methods: We used data from the observational cohort study ENROLL-HD. Clinical assessments and medication are recorded annually for 19540 pwHD and 6010 controls. We determined an episode of depression and anxiety as >1 for both severity and frequency Problem Behaviours Assessment(PBAs) depressed mood item and anxiety item respectively. We classed antidepressants as SSRI, SNRI, TCA, Unique, TeCA (tetracyclic antidepressant), NDRI (noradrenaline – dopamine reuptake inhibitor), phenylpiperazine. We used logistic models to determine the effect of case status on probability of antidepressant treatment and multinomial models to determine the effect of region and case status on antidepressant class. Results: We found that rates of both depression(46.06% vs 32.42%) and anxiety(50.23% vs 37.47%) were higher in pwHD than controls. Even accounting for severity, pwHD were significantly more likely to receive an antidepressant than controls for both depression(OR 3.48,p<2×10 −16 ) and anxiety(OR 4.34,p<2×10 −16 ). Accounting for regional variation, pwHD were more likely than controls to receive a TeCA for depression(OR 2.1,p=1.2×10 −7 ) or anxiety(OR 4.2,p=0.00025); and less likely to receive an NDRI for depression than controls(OR 0.78,p=0.022). There was substantial regional variation in antidepressant class selection for pwHD. Conclusions: Anxiety and Depression are treated differently in pwHD and controls: the lack of an evidence base to justify this underscores the need for a clinical trial of antidepressants for depression and anxiety in pwHD.